Indeed, therapeutic use of monoclonal antibody or chimeric antigen receptor-modified T cell targeting CLL-1 has demonstrated to be effective in reducing AML burden in preclinical and clinical trials [14, 16–23]. Here, CLEC12A is linked to acute myeloid leukemia.